Effect of BMY-28100, a new cephalosporin, on Staphylococcus aureus nasal carriage
Department of Quantitative Health Sciences
Adult; Carrier State; Cephalosporins; Humans; Male; Nasal Cavity; Staphylococcal Infections; Staphylococcus aureus
Bioinformatics | Biostatistics | Epidemiology | Health Services Research
In order to examine the in vivo activity of BMY-28100, serial quantitative nasal cultures were taken from 52 nasal carriers of Staphylococcus aureus following administration of the antimicrobial. Nasal carriage rates and mean log titers decreased significantly during (days 2-4 and 5-8) and following (days 1-2 and 6-7) treatment. No change in antibiotic sensitivities was noted in follow-up isolates, and the MIC90 remained at 2mcg/ml. BMY-28100 demonstrated good in vivo activity against Staphylococcus aureus.
Rights and Permissions
Citation: Eur J Clin Microbiol. 1987 Dec;6(6):679-81.
European journal of clinical microbiology
Atmar, R. L.; Allen, M. L.; Freiman, J.; Kiefe, Catarina I.; Ehrman, S.; and Greenberg, S. B., "Effect of BMY-28100, a new cephalosporin, on Staphylococcus aureus nasal carriage" (1987). Quantitative Health Sciences Publications and Presentations. 163.